AYTU BIOPHARMA, INC: 10-Q filed 2015-05-19
What AYTU BIOPHARMA, INC reported in its quarterly report filed 2015-05-19 (fiscal Q3 2015): 28 published measures, 69 facts as tagged in accession 0001193125-15-193527.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-05-19
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001193125-15-193527 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYTU BIOPHARMA, INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 10,201,465 | USD | |
| At 2014-06-30 | 12,028,964 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 9,650,209 | USD | |
| At 2014-06-30 | 6,659,558 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 551,256 | USD | |
| At 2014-06-30 | 5,369,406 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,491,202 | USD | |
| At 2014-06-30 | 2,639,650 | USD | |
| At 2014-03-31 | 4,121,044 | USD | |
| At 2013-06-30 | 2,913,701 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -1,842,189 | USD | 90 |
| 2014-07-01 to 2015-03-31 | -5,567,960 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -1,680,377 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -3,852,119 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 23,829 | USD | 90 |
| 2014-07-01 to 2015-03-31 | 79,746 | USD | 274 |
| 2014-01-01 to 2014-03-31 | 12,500 | USD | 90 |
| 2013-07-01 to 2014-03-31 | 37,500 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | -12,609,799 | USD | |
| At 2014-06-30 | -7,041,839 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | -23,910 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -322,569 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -549,158 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 36,591 | USD | |
| At 2014-06-30 | 57,246 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 749,810 | USD | 274 |
| 2013-07-01 to 2014-03-31 | 385,342 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,650,454 | USD | |
| At 2014-06-30 | 3,314,717 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 36,052 | USD | 90 |
| 2014-07-01 to 2015-03-31 | 110,900 | USD | 274 |
| 2014-01-01 to 2014-03-31 | 11,980 | USD | 90 |
| 2013-07-01 to 2014-03-31 | 11,662 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 9,202,888 | USD | |
| At 2014-06-30 | 6,092,279 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 546,346 | USD | |
| At 2014-06-30 | 649,504 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 646,472 | USD | |
| At 2014-06-30 | 699,563 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,036 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 11,233 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 694,180 | USD | 90 |
| 2014-07-01 to 2015-03-31 | 2,418,125 | USD | 274 |
| 2014-01-01 to 2014-03-31 | 1,237,854 | USD | 90 |
| 2013-07-01 to 2014-03-31 | 2,640,525 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 19,435,402 | shares |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 551,256 | USD | |
| At 2014-06-30 | 5,369,406 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -1,842,189 | USD | 90 |
| 2014-07-01 to 2015-03-31 | -5,591,870 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -2,002,946 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -4,401,277 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 1,087,788 | USD | 90 |
| 2014-07-01 to 2015-03-31 | 2,986,597 | USD | 274 |
| 2014-01-01 to 2014-03-31 | 737,027 | USD | 90 |
| 2013-07-01 to 2014-03-31 | 1,715,001 | USD | 274 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 73,746 | USD | 274 |
| 2013-07-01 to 2014-03-31 | 63,596 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -36,052 | USD | 90 |
| 2014-07-01 to 2015-03-31 | -110,900 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -11,980 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -11,662 | USD | 274 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | -23,910 | USD | 274 |
| 2013-07-01 to 2014-03-31 | -549,159 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 1,036 | USD | 274 |
| 2013-07-01 to 2014-03-31 | -24,000 | USD | 274 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 11,233 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | -103,158 | USD | 274 |
| 2013-07-01 to 2014-03-31 | 582,899 | USD | 274 |
Inspect the source
- Entity
- AYTU BIOPHARMA, INC / CIK 0001385818
- Captured
- 2026-09-20T07:58:53.461Z
- SEC response SHA-256
3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))